ArticleCancer medicine2020
MiR-5683 suppresses glycolysis and proliferation through targeting pyruvate dehydrogenase kinase 4 in gastric cancer.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Identification of a Circular RNA as a Potential Diagnostic and Prognostic Biomarker in Breast Cancer Through Integrated Bioinformatic and Experimental Analyses.Analytical science advances · 2026Article
- Time- and dose-dependent regulation of circular RNAs in the response of triple-negative breast cancer cells to ionizing radiation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- MicroRNA-597 Suppresses Gastric Cancer Invasion and Progression viaInternational journal of molecular sciences · 2026Article
- Integrated bioinformatics and tissue-based validation reveal the oncogenic role of hsa_circ_0043256 and hsa_circ_0004789 in gastric cancer.Biochemistry and biophysics reports · 2026Article
- Profiling and functional analysis of exosomal circRNAs from EBV-associated gastric carcinoma CSCs.Journal of cancer research and clinical oncology · 2026Article
- PDK4 as a tumor suppressor in gastric cancer: implications for metabolic regulation, immune modulation, and prognostic potential.Discover oncology · 2025Article
- Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer.Frontiers in immunology · 2025Article
- Advances in glycolysis research in gastric cancer: molecular mechanisms, regulatory networks, and therapeutic potential.Frontiers in oncology · 2025Review
- Article
- LncRNA CARMN m6A demethylation by ALKBH5 inhibits mutant p53-driven tumour progression through miR-5683/FGF2.Clinical and translational medicine · 2024Article
- Pan-cancer analysis reveals PDK family as potential indicators related to prognosis and immune infiltration.Scientific reports · 2024Article
- Deficiency of TOP1MT enhances glycolysis through the stimulation of PDK4 expression in gastric cancer.Cancer & metabolism · 2024Article
- Role of microRNAs in glycolysis in gynecological tumors (Review).International journal of oncology · 2023Review
- Transposable elements contribute to the spatiotemporal microRNA landscape in human brain development.RNA (New York, N.Y.) · 2022Article
- Bioinformatics analysis of potential Key lncRNA-miRNA-mRNA molecules as prognostic markers and important ceRNA axes in gastric cancer.American journal of cancer research · 2022Article
- The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.Frontiers in immunology · 2022Article
- Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes.The pharmacogenomics journal · 2021Article
- Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.Histology and histopathology · 2021Review
- Prognostic value of a novel glycolysis-related gene expression signature for gastrointestinal cancer in the Asian population.Cancer cell international · 2021Article
- The Molecular Roles and Clinical Implications of Non-Coding RNAs in Gastric Cancer.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most deadly malignancies at global scale, and is particularly common in eastern Asia. MicroRNA-5683 (miR-5683) was confirmed to be downregulated in GC by analyzing data from the Cancer Genome Atlas. We packaged miR-5683-mimics and miR-5683-inhibitors into lentivirus vectors and transfected them into GC cells. MiR-5683 expression and possible target genes were detected by employing quantitative real-time polymerase chain reaction. In vitro, cell proliferation and apoptosis were analyzed using CCK-8, colony formation assay, and flow cytometric assay. We verified the direct interaction between miR-5683 and the possible downstream target gene pyruvate dehydrogenase kinase 4 (PDK4) through luciferase reporter assay. The role of miR-5683 in vivo was explored by injecting stably transfected GC cells subcutaneously into nude mice. Here we show that miR-5683 was downregulated in GC and the decreased level of miR-5683 enhances GC cell proliferation and impairs apoptosis. Tumor oncogene PDK4, which is associated with GC overall survival and disease-free survival, has been identified as the target gene of miR-5683. Besides, we demonstrate that the inhibition of miR-5683 promotes glycolysis by upregulating the PDK4 expression, thus leading to GC progression. Our study determines that miR-5683 represses GC glycolysis and progression through targeting PDK4. MiR-5683 overexpression may thus become a new treatment strategy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.